Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 16/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201876 | 0.89 | PIK3CA (0.61) | HDAC6PIK3CAPIK3CBPIK3CGPI4KB | |
| SCHEMBL12432945 | 0.89 | HDAC6 (0.53) | HDAC6TRPV1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL13447882 | 0.89 | HDAC6 (0.53) | HDAC6TRPV1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL2705051 | 0.87 | HDAC6 (0.52) | HDAC6TRPV1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL2967925 | 0.84 | CYP1A2 (0.61) | HDAC6TRPV1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL4985555 | 0.82 | HDAC6 (0.71) | HDAC6TRPV1 | |
| SCHEMBL19058424 | 0.81 | HDAC6 (1.00) | HDAC6TRPV1 | |
| SCHEMBL31398710 | 0.81 | HDAC1 (0.51) | HDAC6PIK3CAPIK3CBPIK3CGPI4KB | |
| SCHEMBL2970236 | 0.81 | NPC1 (0.71) | TRPV1PIK3CAPIK3CBPIK3CGPI4KB | |
| SCHEMBL31120903 | 0.81 | NPC1 (0.71) | TRPV1PIK3CAPIK3CBPIK3CGPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602812-B | Bicyclic hydroxamic acids useful as inhibitors of histone deacetylase activity in mammals | 坎塞拉有限公司 | 2021-11-02 | — | — | CN | disclosed |
| EP-3394052-B1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | KANCERA AB (SE) | 2020-05-19 | — | — | US | disclosed |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2019-09-19 | — | — | US | disclosed |
| EP-3394052-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | Kancera AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| CN-108602812-A | It can be used as the bicycle hydroxamic acid compound of the inhibitor of mammal histone deacetylase activity | 坎塞拉有限公司 | 2018-09-28 | — | — | CN | disclosed |
| WO-2017108282-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2017-06-29 | — | — | WO | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-05-17 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122918-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, ARG1 | HDAC6 2661/4885TRPV1 3895/4885PIK3CA 2733/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | HDAC6 2565/4885TRPV1 3816/4885PIK3CA 3048/4885 |
| US-10654814-B2 | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885TRPV1 4645/4885PIK3CA 2101/4885 |
| US-20190284147-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | HDAC1, HDAC11, HDAC10 | HDAC6 10/4885TRPV1 4645/4885PIK3CA 2101/4885 |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | HDAC6 1044/4885TRPV1 3409/4885PIK3CA 4279/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | HDAC6 2483/4885TRPV1 3827/4885PIK3CA 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.